BioSpace News Archive

Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that Annoroad, a leading international genomics center in China, has added two more Sequel® II Systems to its facility, bringing their total up to four Sequel II Systems, to meet the growing demand for long-read sequencing services in basic research, agriculture, human health, and other areas.

Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all investors that purchased Abiomed, Inc.

SnapMD, an award-winning full-service enterprise telehealth technology innovator and solutions provider, today announced it has successfully completed a meticulous third-party examination of its data security processes and controls under the SOC 2 + HITRUST framework, a significant, two-tiered healthcare technology compliance accomplishment.

The latest Morgan Stanley Investor Pulse Poll finds that high net worth (HNW) investors are increasingly attracted to digital technology while at the same time concerned about cybersecurity.

Phase One patient data from a potential therapy targeting a single KRAS mutation, formerly considered “undruggable,” has been introduced in 2019.

Transgene (Paris:TNG), a biotech company designing and developing virus-based immunotherapies for the treatment of solid tumors, provides an update on the interim futility analysis of the PHOCUS study of Pexa-Vec in liver cancer.

Dr. Laurie Shanderson, Founding Dean of Northcentral University’s School of Health Sciences, has received the New Program of the Year award from the Association of University Programs in Health Administration.

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today reported financial results for the quarter ended June 30, 2019.

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, and Avedro, Inc. (Nasdaq: AVDR), a leading hybrid ophthalmic pharmaceutical and medical technology company focused on treating corneal disease and disorders, today announced that the companies have entered into a definitive merger agreement

22nd Century Group, Inc., a plant biotechnology company that is focused on tobacco harm reduction, Very Low Nicotine Content tobacco and hemp/cannabis research, announced that the Company filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2019 with the U.S. Securities and Exchange Commission.